APA (7th ed.) Citation

MV, M., S, T., H, Q., P, R., M, B., L, P., . . . MA, D. (2025). Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials. Blood advances, 9(22), 5708. https://doi.org/10.1182/bloodadvances.2025016949

Chicago Style (17th ed.) Citation

MV, Mateos, et al. "Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 Trials." Blood Advances 9, no. 22 (2025): 5708. https://doi.org/10.1182/bloodadvances.2025016949.

MLA (9th ed.) Citation

MV, Mateos, et al. "Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 Trials." Blood Advances, vol. 9, no. 22, 2025, p. 5708, https://doi.org/10.1182/bloodadvances.2025016949.